Loren, J.
20627  Ergebnisse:
Personensuche X
?
3

OBINUTUZUMAB THERAPY IN PATIENTS WITH MARGINAL ZONE AND MAN..:

Hughes, M.E. ; Suen, C. ; Namoglu, E....
Hematological Oncology.  37 (2019)  S2 - p. 404-405 , 2019
 
?
4

REAL WORLD OUTCOMES OF OBINUTUZUMAB MONOTHERAPY IN PATIENTS..:

Hughes, M.E. ; Suen, C. ; Namoglu, E....
Hematological Oncology.  37 (2019)  S2 - p. 378-379 , 2019
 
?
 
?
6

Transplant Physician Perceptions and Practice Patterns Rega..:

Majhail, N.S. ; Quinn, G. ; Brzauskas, R....
Biology of Blood and Marrow Transplantation.  17 (2011)  2 - p. S240 , 2011
 
?
7

Prophylactic Administration Of Ex VIVO Co-Stimulated Donor ..:

Goldstein, S.C. ; Levine, B. ; Smith, J....
Biology of Blood and Marrow Transplantation.  15 (2009)  2 - p. 130 , 2009
 
?
 
?
9

315: Similar Survival after Sibling vs Unrelated Donor Allo..:

Stein, S. ; Goldstein, S.C. ; Smith, J....
Biology of Blood and Marrow Transplantation.  14 (2008)  2 - p. 116 , 2008
 
?
10

251: Low rates of chimerism occur when alemtuzumab is added..:

Kasner, M. ; Loren, A. ; Stein, S....
Biology of Blood and Marrow Transplantation.  13 (2007)  2 - p. 92 , 2007
 
?
11

Endoscopic sphincterotomy with or without cholecystectomy f..:

SIDDIQUI, A. A. ; MITROO, P. ; KOWALSKI, T..
Alimentary Pharmacology & Therapeutics.  24 (2006)  7 - p. 1059-1066 , 2006
 
?
12

A survey of oesophageal cancer: pathology, stage and clinic..:

SCHLANSKY, B. ; DIMARINO JR, A. J. ; LOREN, D....
Alimentary Pharmacology & Therapeutics.  23 (2006)  5 - p. 587-593 , 2006
 
?
13

Myeloablative vs non-myeloablative conditioning with alloge..:

Hewitt, M. ; Porter, D.L. ; Hummel, K....
Biology of Blood and Marrow Transplantation.  11 (2005)  2 - p. 27-28 , 2005
 
?
 
?
15

Variations of biochemical parameters along a transect in th..:

Abrahamsson, K. ; Bertilsson, S. ; Chierici, M....
Deep Sea Research Part II: Topical Studies in Oceanography.  51 (2004)  22-24 - p. 2745-2756 , 2004
 
1-15
Mehr Literatur finden